Potential Protective Role of Thymoquinone on Experimentally-induced Alzheimer Rats

Main Article Content

Mohammad Fiasal Zaher
Mohamed Abdelfattah Bendary
Gamal Saeed Abd El-Aziz
Ahmed Shaker Ali


Aim: To evaluate the neuroprotective potential of thymoquinine (TQ) on the oxidative stress status of the brain in aluminum chloride (AlCl3)-induced AD in rats.

Study Design:  Animal research study.

Place and Duration of Study: King Fahd Medical Research Center (KFMRC), King Abdulaziz University, Saudi Arabia, April 2018-June 2019.

Methodology: Thirty adult male Sprague Dawley albino rats were randomly divided into 3 groups. Group 1 (Control). Group 2 (AD): supplemented orally with AlCl3 (17 mg/kg/day) for 4 weeks. Group 3 (TQ/AD): supplemented concomitantly with oral TQ (10 mg/kg/day) and AlCl3 (17 mg/kg/day) for 4 weeks. At the end of the experiment, spatial working memory was assessed using the Y-maze spontaneous alternation test. Then, serum levels of malondialdehyde (MDA) and glutathione peroxidase enzyme (GPX) were assessed. Then, the rats were sacrificed, and the brain was isolated, and a light microscopic examination of the hippocampus was performed. Finally, the brain homogenate content of Aβ, tau protein and acetylcholine were biochemically determined.

Results: The AD group showed a significant decreased in the spontaneous alteration performance (SAP %) in Y-maze. Also, in the AD group, serum MDA, Aβ and tau protein were significantly increased with a significant decrease of serum GPX and acetylcholine. Examination of H&E-stained sections of the hippocampus of the AD group revealed decreased thickness and disorganization of the pyramidal cell layer of CA1 and CA3 where many pyramidal cells lost their triangular shape and appeared shrunken. The molecular and polymorphic layers showed increased glial cells and congested blood capillaries. The dentate gyrus showed marked disorganization with some cell loss. Co-administration of TQ with AlCl3 in TQ/AD group, improved SAP % and significantly decreased serum MDA, Aβ, tau protein. It also increased serum GPX and acetylcholine levels. Also, TQ partially attenuated the histopathological changes in the hippocampus.

Conclusion: TQ could mitigate the oxidative stress markers, neurodegenerative indices and histopathological alteration encountered in AD that all reflected on improving the cognitive behavior. This may implement TQ as an adjuvant medical strategy in ameliorating AD.

Alzheimer's disease, AlCl3, thymoquinone, oxidative stress, Aβ, tau protein, acetylcholine, Y-maze.

Article Details

How to Cite
Fiasal Zaher, M., Abdelfattah Bendary, M., Saeed Abd El-Aziz, G., & Shaker Ali, A. (2019). Potential Protective Role of Thymoquinone on Experimentally-induced Alzheimer Rats. Journal of Pharmaceutical Research International, 31(6), 1-18. https://doi.org/10.9734/jpri/2019/v31i630358
Original Research Article


Anand R, Gill KD, Mahdi AA. Therapeutics of Alzheimer's disease: Past, present and future. Neuropharmacology. 2014;76(1):27-50.

Clark CM. Clinical manifestations and diagnostic evaluation of patients with Alzheimer’s disease. Neurodegenerative dementias. 2000;95-114.

Tanzi RE, Bertram L. Twenty years of the Alzheimer’s disease amyloid hypothesis: a genetic perspective. Cell. 2005;120(4):545-55.

Deshpande A, Mina E, Glabe C, Busciglio J. Different conformations of amyloid β induce neurotoxicity by distinct mechanisms in human cortical neurons. Journal of Neuroscience. 2006;26(22):6011-8.

Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer’s disease. Alzheimer's & dementia. 2007;3(3):186-91.

Korczyn AD, Vakhapova V. The prevention of the dementia epidemic. Journal of the neurological sciences. 2007;257(1-2):2-4

Bachurin SO, Bovina EV, Ustyugov AA. Drugs in clinical trials for Alzheimer's disease: the major trends. Medicinal research reviews. 2017;37(5):1186-225.

Bajda M, Guzior N, Ignasik M, Malawska B. Multi-target-directed ligands in Alzheimer's disease treatment. Current medicinal chemistry. 2011;18(32):4949-75.

Zhang J, Zhen YF, Song LG, Kong WN, Shao TM, Li X, et al. Salidroside attenuates beta-amyloid-induced cognitive deficits via modulating oxidative stress and inflammatory mediators in rat hippocampus. Behavioral Brain Research. 2013;244:70-81.

Tariot PN, Federoff HJ. Current treatment for Alzheimer's disease and prospects. Alzheimer disease & associated disorders. 2003;17:S105-13.

Mendiola-Precoma J, Berumen LC, Padilla K, Garcia-Alcocer G. Therapies for prevention and treatment of Alzheimer’s disease. BioMed research international. 2016;2016:1-17. Available:http://dx.doi.org/10.1155/2016/2589276

Ahmad A, Husain A, Mujeeb M, Khan SA, Najmi AK, Siddique NA, et al. A review on the therapeutic potential of Nigella sativa: A miracle herb. Asian Pacific journal of tropical biomedicine. 2013;3(5):337-52.

Amin B, Hosseinzadeh H. Black cumin (Nigella sativa) and its active constituent, thymoquinone: an overview of the analgesic and anti-inflammatory effects. Planta medica. 2016;82(01/02):8-16.

Hosseinzadeh H, Taiari S, Nassiri-Asl M. Effect of thymoquinone, a constituent of Nigella sativa L., on ischemia-reperfusion in rat skeletal muscle. Naunyn-Schmiedeberg's archives of pharmacology. 2012;385(5):503-8.

Javidi S, Razavi BM, Hosseinzadeh H. A review of neuropharmacology effects of Nigella sativa and its main component, thymoquinone. Phytotherapy research. 2016;30(8):1219-29.

Ghoneim FM, Khalaf HA, Elsamanoudy AZ, El-Khair SM, Helaly AM, Mahmoud EH, et al. Protective effect of chronic caffeine intake on gene expression of brain-derived neurotrophic factor signaling and the immunoreactivity of glial fibrillary acidic protein and Ki-67 in Alzheimer’s disease. International Journal of Clinical and Experimental Pathology. 2015;8(7):7710.

Krasovskiĭ GN, Vasukovich LY, Chariev OG. Experimental study of biological effects of leads and aluminum following oral administration. Environmental Health Perspectives. 1979;30:47-51.

Ince S, Kucukkurt I, Demirel HH, Turkmen R, Zemheri F, Akbel E. The role of thymoquinone as antioxidant protection on oxidative stress induced by imidacloprid in male and female Swiss albino mice. Toxicological & Environmental Chemistry. 2013;95(2):318-29.

Paul CM, Magda G, Abel S. Spatial memory: Theoretical basis and comparative review on experimental methods in rodents. Behavioral Brain Research. 2009;203(2):151-64.

Zhao H, Wang L, Chen L, Zhang J, Sun W, Salvi RJ, et al. Temporary conductive hearing loss in early life impairs spatial memory of rats in adulthood. Brain and behavior. 2018;8(7):e01004.

Wall PM, Messier C. Infralimbic kappa opioid and muscarinic M1 receptor interactions in the concurrent modulation of anxiety and memory. Psychopharmacology. 2002; 160(3):233-44.

Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Analytical biochemistry. 1979;95(2):351-8.

Flohé L, Günzler WA. [12] Assays of glutathione peroxidase. Methods in enzymology. 1984;105:114-120.

Zhao Z, Ho L, Wang J, Qin W, Festa ED, Mobbs C, et al. Connective Tissue Growth Factor (CTGF) expression in the brain is a downstream effector of insulin resistance-associated promotion of Alzheimer’s disease β-amyloid neuropathology. The FASEB Journal. 2005;19(14):2081-2.

Dwivedi S, Nagarajan R, Hanif K, Siddiqui HH, Nath C, Shukla R. Standardized extract of Bacopa monniera attenuates okadaic acid induced memory dysfunction in rats: Effect on Nrf2 pathway. Evidence-Based Complementary and Alternative Medicine. 2013;2013:1-18.

Oswald C, Smits SH, Höing M, Sohn-Bösser L, Dupont L, Le Rudulier D, et al. Crystal structures of the choline/acetylcholine substrate-binding protein ChoX from Sinorhizobium meliloti in the liganded and unliganded-closed states. Journal of Biological Chemistry. 2008;283(47):32848-59.

Bancroft JD, Gamble M. Theory and practice of histology techniques. 6th ed. Edinburgh: Churchill Livingstone; 2008.

Petrie A, Sabin C. Medical Statistics at a Glance. 2nd ed. Oxford: Blackwell Publishing Ltd; 2005.

Pagnier GJ, Kastanenka KV, Sohn M, Choi S, Choi SH, Soh H, et al. Novel botanical drug DA-9803 prevents deficits in Alzheimer’s mouse models. Alzheimer's research & therapy. 2018;10(1):11.

Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, et al. Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: Potential factors in amyloid plaque formation. Journal of Neuroscience. 2006;26(40):10129-40.

Abulfadl YS, El-Maraghy NN, Ahmed AE, Nofal S, Abdel-Mottaleb Y, Badary OA. Thymoquinone alleviates the experimentally induced Alzheimer’s disease inflammation by modulation of TLRs signaling. Human & experimental toxicology. 2018;37(10):1092-104.

Bargi R, Asgharzadeh F, Beheshti F, Hosseini M, Sadeghnia HR, Khazaei M. The effects of thymoquinone on hippocampal cytokine level, brain oxidative stress status and memory deficits induced by lipopolysaccharide in rats. Cytokine. 2017; 96:173-84.

Dalli T, Beker M, Terzioglu-Usak S, Akbas F, Elibol B. Thymoquinone activates MAPK pathway in hippocampus of a streptozotocin-treated rat model. Biomedicine & Pharmacotherapy. 2018;99:391-401.

Barrientos RM, Higgins EA, Biedenkapp JC, Sprunger DB, Wright-Hardesty KJ, Watkins LR, et al. Peripheral infection and aging interact to impair hippocampal memory consolidation. Neurobiology of aging. 2006; 27(5):723-32.

Castellani RJ, Zhu X, Lee HG, Smith MA, Perry G. Molecular pathogenesis of Alzheimer’s disease: Reductionist versus expansionist approaches. International Journal of Molecular Sciences. 2009;10(3): 1386-406.

Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radical Biology and Medicine. 1997;23(1):134-47.

Abe T, Tohgi H, Isobe C, Murata T, Sato C. Remarkable increase in the concentration of 8‐hydroxyguanosine in cerebrospinal fluid from patients with Alzheimer's disease. Journal of Neuroscience Research. 2002; 70(3):447-50.

Min JY, Min KB. Serum lycopene, lutein and zeaxanthin, and the risk of Alzheimer's disease mortality in older adults. Dementia and geriatric cognitive disorders. 2014;37(3-4):246-56.

Weydert CJ, Cullen JJ. Measurement of superoxide dismutase, catalase and glutathione peroxidase in cultured cells and tissue. Nature Protocols. 2010;5(1):51.

Perez M, Cuadros R, Smith MA, Perry G, Avila J. Phosphorylated, but not native, tau protein assembles following reaction with the lipid peroxidation product, 4‐hydroxy‐2 ‐nonenal. Febs Letters. 2000;486(3):270-4.

Casado Á, López-Fernández ME, Casado MC, de La Torre R. Lipid peroxidation and antioxidant enzyme activities in vascular and Alzheimer dementias. Neurochemical Research. 2008;33(3):450-8.

Mehri S, Shahi M, Razavi BM, Hassani FV, Hosseinzadeh H. Neuroprotective effect of thymoquinone in acrylamide-induced neurotoxicity in Wistar rats. Iranian journal of basic medical sciences. 2014;17(12):1007.

Alhebshi AH, Gotoh M, Suzuki I. Thymoquinone protects cultured rat primary neurons against amyloid β-induced neurotoxicity. Biochemical and biophysical Research Communications. 2013;433(4): 362-7.

Al-Majed AA, Al-Omar FA, Nagi MN. Neuroprotective effects of thymoquinone against transient forebrain ischemia in the rat hippocampus. European Journal of Pharmacology. 2006;543(1-3):40-7.

Wang Z, Wei X, Yang J, Suo J, Chen J, Liu X, et al. Chronic exposure to aluminum and risk of Alzheimer’s disease: A meta-analysis. Neuroscience letters. 2016;610:200-6.

Haque R, Uddin SN, Hossain A. Amyloid Beta (Aβ) and Oxidative Stress: Progression of Alzheimer’s Disease. 2018;11(1):1-10.
DOI: 10.19080/AIBM.2018.11.555802

Kandimalla R, Vallamkondu J, Corgiat EB, Gill KD. Understanding Aspects of Aluminum Exposure in Alzheimer's Disease Development. Brain pathology. 2016;26(2): 139-54.

Catricala S, Torti M, Ricevuti G. Alzheimer disease and platelets: How’s that relevant. Immunity & Ageing. 2012;9(1):20.

Praticò D, Uryu K, Sung S, Tang S, Trojanowski JQ, Lee VM. Aluminum modulates brain amyloidosis through oxidative stress in APP transgenic mice. The FASEB Journal. 2002;16(9):1138-40.

Chen SM, Fan CC, Chiue MS, Chou C, Chen JH, Hseu RS. Hemodynamic and neuropathological analysis in rats with aluminum trichloride-induced Alzheimer's disease. PloS one. 2013;8(12):e82561.

Panahi N, Mahmoudian M, Mortazavi P, Hashjin GS. Effects of berberine on β-secretase activity in a rabbit model of Alzheimer's disease. Archives of medical science: AMS. 2013;9(1):146.

Kawahara M, Kato M, Kuroda Y. Effects of aluminum on the neurotoxicity of primary cultured neurons and on the aggregation of β-amyloid protein. Brain research bulletin. 2001;55(2):211-7.

Altmann P, Cunningham J, Dhanesha U, Ballard M, Thompson J, Marsh F. Disturbance of cerebral function in people exposed to drinking water contaminated with aluminium sulphate: Retrospective study of the Camelford water incident. Bmj. 1999; 319(7213):807-11.

Rondeau V, Commenges D, Jacqmin-Gadda H, Dartigues JF. Relation between aluminum concentrations in drinking water and Alzheimer's disease: An 8-year follow-up study. American Journal of Epidemiology. 2000;152(1):59-66.

Kawahara M, Kato-Negishi M. Link between aluminum and the pathogenesis of Alzheimer's disease: The integration of the aluminum and amyloid cascade hypotheses. International journal of Alzheimer’s disease. 2011;2011:1-17. Available:http://dx.doi:10.4061/2011/276393.

Exley C. Human exposure to aluminium. Environmental Science: Processes & Impacts. 2013;15(10):1807-16.

Khan A, Vaibhav K, Javed H, Khan MM, Tabassum R, Ahmed ME, et al. Attenuation of Aβ-induced neurotoxicity by thymoquinone via inhibition of mitochondrial dysfunction and oxidative stress. Molecular and cellular biochemistry. 2012;369(1-2):55-65.

Wu XL, Piña-Crespo J, Zhang YW, Chen XC, Xu HX. Tau-mediated neurodegeneration and potential implications in diagnosis and treatment of Alzheimer's disease. Chinese Medical Journal. 2017; 130(24):2978.

Saunders J, Donhauser Z. A Functional Analysis of the Projection Domain of the Microtubule Associated Protein Tau Using Force Spectroscopy. 2013;27(1s):1036-40.

Ballatore C, Smith AB, III, Lee V M Y. Trojanowski JQ, Brunden KR. Microtubule stabilization In: Michael S Wolfe, editor. Developing Therapeutics for Alzheimer’s Disease progress and challenges. 1st ed. London: Elsevier; 2016.

Delacourte A, Sergeant N, Wattez A, Maurage CA, Lebert F, Pasquier F, et al. Tau aggregation in the hippocampal formation: an aging or a pathological process?. Experimental gerontology. 2002;37(10-11): 1291-6.

Wang JZ, Xia YY, Grundke-Iqbal I, Iqbal K. Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration. Journal of Alzheimer's Disease. 2013;33(s1):S123-39.

Bulinski JC, McGraw TE, Gruber D, Nguyen HL, Sheetz MP. Overexpression of MAP4 inhibits organelle motility and trafficking in vivo. Journal of cell science. 1997;110(24): 3055-64.

Trinczek B, Ebneth A, Mandelkow EM, Mandelkow E. Tau regulates the attachment/detachment but not the speed of motors in microtubule-dependent transport of single vesicles and organelles. Journal of cell science. 1999;112(14):2355-67.

Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow EM. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. The Journal of Cell Biology. 2002; 156(6):1051-63.

Iqbal K, Gong CX, Liu F. Microtubule-associated protein tau as a therapeutic target in Alzheimer's disease. Expert opinion on therapeutic targets. 2014;18(3):307-18.

Green KN and Schreiber S. Advances in Our Understanding of the Pathophysiology of Alzheimer's Disease. US Neurology. 2010; 6(1):22–31.

Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53(3):337-51.

Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309(5733):476-81.

Yassin N, El-Shenawy S, Mahdy KA, Gouda N, Marrie A, Farrag A, et al. Effect of Boswellia serrata on Alzheimer’s disease induced in rats. J Arab Soc Med Res. 2013;8:1-11.

Claassen JA, Jansen RW. Cholinergically mediated augmentation of cerebral perfusion in alzheimer's disease and related cognitive disorders: the cholinergic–vascular hypothesis. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2006;61(3):267-71.

Van Beek AH, Claassen JA. The cerebrovascular role of the cholinergic neural system in Alzheimer's disease. Behavioural brain research. 2011;221(2):537-42.

Hunter JM, Kwan J, Malek-Ahmadi M, Maarouf CL, Kokjohn TA, Belden C, et al. Morphological and pathological evolution of the brain microcirculation in aging and Alzheimer’s disease. PloS one. 2012;7(5): e36893.

Hampel H, Mesulam MM, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, et al. The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain. 2018;141(7):1917-33.

Divya, P. Brief overview on alzheimer`s disease with recent treatment. Asian journal of pharmaceutical education and research. 2014;3(4):1-9.

DAVIS T. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 1976;2:1403.

Pákáski M, Kálmán J. Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease. Neurochemistry International. 2008;53(5):103-11.

Richter JA, Perry EK, Tomlinson BE. Acetylcholine and choline levels in post-mortem human brain tissue: Preliminary observations in Alzheimer's disease. Life Sciences. 1980;26(20):1683-9.

Teaktong T, Graham AJ, Court JA, Perry RH, Jaros E, Johnson M, et al. Nicotinic acetylcholine receptor immunohistochemistry in Alzheimer's disease and dementia with Lewy bodies: Differential neuronal and astroglial pathology. Journal of the Neurological Sciences. 2004;225(1-2):39-49.

Ramos-Rodriguez JJ, Pacheco-Herrero M, Thyssen D, Murillo-Carretero MI, Berrocoso E, Spires-Jones TL, et al. Rapid β-amyloid deposition and cognitive impairment after cholinergic denervation in APP/PS1 mice. Journal of Neuropathology & Experimental Neurology. 2013;72(4):272-85.

Field RH, Gossen A, Cunningham C. Prior pathology in the basal forebrain cholinergic system predisposes to inflammation-induced working memory deficits: Reconciling inflammatory and cholinergic hypotheses of delirium. Journal of Neuroscience. 2012; 32(18):6288-94.

Jukic M, Politeo O, Maksimovic M, Milos M, Milos M. In vitro acetylcholinesterase inhibitory properties of thymol, carvacrol and their derivatives thymoquinone and thymohydroquinone. Phytotherapy Research. 2007;21(3):259-61.

Padurariu M, Ciobica A, Mavroudis I, Fotiou D, Baloyannis S. Hippocampal neuronal loss in the CA1 and CA3 areas of Alzheimer’s disease patients. Psychiatr Danub. 2012;24: 152-8.

Nirmala RN, Shankarbhat K, Urban D. Effect of long term administration of aluminum chloride on oxidative stress and acetylcholin-esterase activity in rat brains. IJPBS. 2013; 3:616-622.

Aly HF, Metwally FM, Ahmed HH. Neuro- protective effects of dehydroepiandrosterone (DHEA) in rat model of Alzheimer’s disease. Acta Biochim Pol. 2011;58:513-20.

Abo El-Khair DM, El-Safti Fel-N, Nooh HZ, ElMehi AE. A comparative study on the effect of high cholesterol diet on the hippocampal CA1 area of adult and aged rats. Anat Cell Biol. 2014;47:117-26.

Pratico D, Trojanowski JQ. Inflammatory hypotheses: Novel mechanisms of Alzheimer’s neurodegeneration and new therapeutic targets? Neurobiol Aging. 2000; 21:441-445.

Lynch MA. The impact of neuroimmune changes on development of amyloid pathology; relevance to Alzheimer’s disease. Immunology. 2014;141:292-301.

Nobakht M, Hoseini SM, Mortazavi P, Sohrabi I, Esmailzade B, Rahbar Rooshandel N, Omidzahir S. Neuro pathological changes in brain cortex and hippocampus in a rat model of Alzheimer’s disease. Iran Biomed J. 2011;15:51-8.

Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1:a006189.

Ciobica A, Padurariu M, Bild W, Stefanescu C. Cardiovascular risk factors as potential markers for mild cognitive impairment and Alzheimer’s disease. Psychiatr Danub. 2011;23:333-340.